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Objectives: This study aimed to compare survival outcomes after hepatic resection (HR) and radiofre-
quency ablation (RFA) in early-stage hepatocellular carcinoma (HCC) at a Western hepatobiliary centre.
Methods: Demographic details, clinicopathologic tumour characteristics and survival outcomes were
compared among non-transplant candidate patients undergoing HR (n = 50) and RFA (n = 60) for
early-stage HCC during 2001–2011.
Results: Patients who underwent HR had larger tumours, a longer length of stay and a higher rate of
postoperative complications. After a median follow-up of 29 months, there were no significant differences
between the treatment groups in 1-, 3- and 5-year overall survival (OS) [RFA group: 86%, 50%, 35%,
respectively; HR group: 88%, 68%, 47%, respectively (P = 0.222)] or disease-free survival (DFS) [RFA
group: 68%, 42%, 28%, respectively; HR group: 66%, 42%, 34%, respectively (P = 0.823)]. The 58
patients who underwent RFA demonstrated ablation success on follow-up computed tomography at
3 months. Of these, 96.5% of patients showed sustained ablation success over the entire follow-up
period. In a subgroup analysis of patients with tumours measuring 2–5 cm, no differences in OS or DFS
emerged between the HR and RFA groups. Similarly, no significant differences in outcomes in patients
with Child–Pugh class A cirrhosis were seen between the RFA and HR groups.
Conclusions: Radiofrequency ablation is comparable with HR in terms of OS and DFS. It is a reasonable
alternative as a first-line treatment for HCC in well-selected patients who are not candidates for
transplant.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy worldwide and the third most common cause of
cancer-related death; an estimated 500 000 deaths from HCC
occur per year.1 It is less common in the western hemisphere;
however, its incidence is increasing.2 The implementation of early
screening guidelines has increased the number of patients diag-
nosed with early-stage HCC.3 For patients who are candidates,
liver transplantation guarantees the best longterm overall survival
(OS) and disease-free survival (DFS) as it removes both the
tumour and the cirrhotic background liver. However, its use is
limited by shortages in donor organ supply and high costs. For
these reasons, limited hepatic resection (HR), for which 5-year
survival rates range from 41% to 72%, has traditionally been seen
as the next best treatment for patients with HCC.4 Unfortunately,
surgical resection is often limited by the degree of liver cirrhosis
and resection rates range between 10% and 37%, even in highly
specialized centres.5
Multiple local ablative treatments have been developed to treat
HCC. These include transarterial chemoembolization, percutane-
ous ethanol injection and radiofrequency ablation (RFA). The last
of these has been increasingly used as a second-line alternative to
surgery for primary and metastatic hepatic malignancies because
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it is superior to other locally ablative modalities, safer and pro-
vides more consistent results in local tumour control.6–8 Its major
usage has been in patients with early-stage HCC and limited liver
reserve, who are unsuitable for surgical resection. Most of the
guidelines for the treatment of HCC recommend HR and RFA as
first- and second-line treatments, respectively, in patients with
good liver function (classified as Child–Pugh class A or B cirrho-
sis) and a single tumour or no more than three tumours each
measuring3 cm.9–11 These guidelines were based on the assump-
tion that surgical resection achieves complete tumour ablation
with a safety margin, although there is no evidence supported by
randomized controlled trials (RCTs) for this.
Whether RFA provides longterm OS and DFS equivalent to
those of HR when it is used as a first-line treatment remains
unclear in cohort studies.12–14 Two RCTs have been performed, but
gave contradictory conclusions.15,16 A recent meta-analysis showed
that HR was superior to RFA, especially for HCC tumours mea-
suring >3 cm, although the low level of evidence in the studies
enrolled in this meta-analysis limits its conclusions. Therefore, the
optimal first-line treatment for early-stage HCC,whether it be HR
or RFA, in patients with well-preserved liver function remains
insufficiently established. Although many studies conducted in
Asia and Europe have compared outcomes between HR and RFA,
this type of comparison has not been properly performed in the
USA. This study sought to retrospectively analyse longterm OS
and DFS in 110 patients with early-stage HCC who were not listed
for liver transplant and who received either RFA or HR as a first-
line treatment.
Materials and methods
Patients
Between January 2000 and September 2011, 1010 patients diag-
nosed with HCC were evaluated at the University of Pittsburgh
Medical Center (UPMC) Liver Cancer Center in Pittsburgh, Penn-
sylvania. A total of 110 patients with newly diagnosed HCC clas-
sified according to the Barcelona Clinic Liver Cancer (BCLC)
system11 as very early/early-stage HCC and in receipt of either HR
(n = 50) or RFA (n = 60) as a first-line treatment were included in
this study. Patients who received or were listed for liver transplan-
tation during the study period were excluded. Patients were not
listed for liver transplant for reasons of active alcohol or illicit
drug abuse, age, severe comorbidities, psychosocial factors,
absence of liver cirrhosis or patient preference. Data were analysed
retrospectively from a prospective institutional review board-
approved hepatic cancer registry. Factors examined included
patient demographics, presence of cirrhosis, aetiology of hepatitis,
Child–Pugh classification, tumour characteristics, treatment
modality and survival outcome.
The diagnosis of HCC was based on the criteria defined in the
practice guidelines of the European Association for the Study of
Liver (EASL) or the American Association for the Study of Liver
Disease (AASLD).10,11 Evaluation included clinical laboratory
values (complete blood count, basic metabolic panel, coagulation
studies, liver function tests), hepatitis screening, analysis for
tumour markers [alpha-fetoprotein (AFP), carcinoembryonic
antigen (CEA), carbohydrate antigen 19-9 (CA 19-9)], and radio-
graphic studies including triphasic helical axial computed tomog-
raphy (CT) and magnetic resonance imaging (MRI). Liver biopsy
was performed when diagnosis could not be determined accord-
ing to laboratory (AFP 400 ng/ml) and radiographic data alone.
Diagnosis and treatment recommendations for all patients were
made at a weekly multidisciplinary liver tumour conference.
Treatment of HCC
All patients were reviewed by a multidisciplinary liver tumour
board comprised of specialists in transplant surgery, surgical and
medical oncology, hepatology and interventional radiology. All
procedures were performed at a single institution (UPMC). In
patients scheduled to undergo HR, the extent of resection was
determined by an experienced surgical team based on the severity
of liver disease, the location of the tumour, and the anticipation of
an adequate non-tumour margin. All RFA procedures were per-
formed in the operating room under general anaesthesia. Open
and laparoscopic approaches were used. Laparoscopic ablation
was usually performed via three laparoscopic ports. Intraoperative
ultrasound was uniformly used to assess the placement of the RFA
probe. Standard protocols for ablation time and power were used.
Tissue biopsy was always obtained from the tumours intraopera-
tively prior to ablation.
Surveillance
All patients were surveyed closely in clinic according to imaging
studies and AFP levels at intervals of 3–6 months. The effect of
RFA was evaluated with contrast-enhanced CT or MRI at
1–3 months after the procedure. Ablation success was defined
according to the appearance of an area equal to or larger than that
of the ablated tumour without contrast enhancement at 3 months
after RFA. Local recurrence was defined as tumour recurrence at
the treated site. A new tumour that appeared elsewhere in the
hepatic parenchyma was defined as a new intrahepatic recurrence.
Recurrences were treated using modalities selected according to
the preference of the patient and the clinical practice of treating
surgeons and clinicians.
Statistics
All patients were followed until death or September 2011. Statis-
tical analysis was performed using spssVersion 17.0 for Windows
(SPSS, Inc., Chicago, IL, USA). Descriptive statistics were used to
analyse sociodemographic and disease-specific variables. Inter-
group comparisons on disease-specific variables were performed
using chi-squared analyses for categorical variables. Rates of OS
and DFS were obtained using Kaplan–Meier survival analyses
(log-rank). In all comparisons, a P-value of 0.05 was considered to
indicate statistical significance.
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Results
Patient demographics
Of the 1010 consecutive patients treated for HCC at the UPMC
Liver Cancer Center, 110 patients presented with early-stage HCC
and were treated with either HR or RFA as first-line therapy.
Patients who received or were listed for liver transplantation or
had Child–Pugh class C cirrhosis were excluded. Demographic
characteristics are summarized in Table 1. There were no signifi-
cant differences between the HR and RFA groups in age, gender,
preoperative AFP level or aetiology of cirrhosis. However, patients
who underwent RFA had significantly smaller tumours and worse
underlying liver function according to Child–Pugh class; however,
there was no difference in Model for End-stage Liver Disease
(MELD) scores between the groups. Cirrhosis was identified in
66.0% of patients in the HR group and 93.3% of patients in the
RFA group. The majority of patients receiving either HR or RFA
were treated for a single tumour nodule (HR group, n = 39; RFA
group, n = 47).
Treatment results
Surgical resection for early-stage HCC was performed in 50
patients and consisted of anatomic lobectomy (n = 8),
segmentectomy/bisegmentectomy (n = 36) or non-anatomic
resection (n = 6). Surgery was performed using an open procedure
in 32 (64.0%) patients and as a minimally invasive laparoscopic or
hand-assisted procedure in 18 (36.0%) patients. Histopathologi-
cal examination showed six (12.0%) poorly differentiated, 27
(54.0%) moderately differentiated and 17 (34.0%) well-
differentiated tumours. Eight (16.0%) specimens had microsatel-
lites and 24 (48.0%) specimens showed microvascular invasion.
Sixty patients with early-stage HCC received RFA as first-line
therapy. The vast majority (95.0%) of RFA procedures were per-
formed laparoscopically. Three (5.0%) patients underwent an
open RFA procedure. Biopsy specimens in the RFA group showed
five (8.3%) poorly differentiated, 36 (60.0%) moderately differen-
tiated and 19 (31.7%) well-differentiated tumours.
The hospital length of stay (LoS) was significantly longer in the
HR group (5.36  2.9 days) than in the RFA group (2.2 
1.85 days) (Table 1). A comparison of patients who underwent
minimally invasive (laparoscopic) RFA (n = 57) with those sub-
jected to minimally invasive HR (n = 17) showed that hospital LoS
was significantly shorter in the laparoscopic RFA subgroup (2.07
 1.32 days vs. 3.61 1.33 days; P < 0.001). Two deaths within the
first 90 days after surgery occurred in the HR group, both in
patients with Child–Pugh class B cirrhosis. No patients in the RFA
group died within 90 days of treatment. The frequency of com-
plications was significantly higher in the HR group (n = 15,
30.0%) than in the RFA group (n = 9, 15.0%) (P = 0.04) (Table 1).
Table 1 Patient characteristics
RFA group (n = 60) HR group (n = 50) P-value
Age, years, mean  SD 65.6  12 66.3  1 0.723
Male gender, n (%) 38 (63.3%) 31 (62.0%) 0.942
AFP, ng/ml, mean  SD 141  507 2730  9991 0.116
Aetiology of cirrhosis 0.853
Hepatitis B only 5.2% 6.4%
Hepatitis C only 48.3% 38.7%
Hepatitis B and C 12.1% 12.9%
Non-viral 34.4% 41.9%
Child–Pugh class 0.03
No cirrhosis 4 (6.7%) 17 (34.0%)
Class A 40 (66.7%) 27 (54.0%)
Class B 16 (26.7%) 6 (12.0%)
MELD score in cirrhosis 8  2 8  3 0.929
Tumour size, cm, mean  SD 2.36  0.94 3.07  1.17 0.001
Number of nodules, n (%) 0.851
1 47 (78.3%) 39 (78.0%)
2 11 (18.3%) 10 (20.0%)
3 2 (3.3%) 1 (2.0%)
Hospital LoS, days, mean  SD 2.2  1.85 5.36  2.9 < 0.01
90-day complications, n (%) 9 (14.7%) 15 (30.0%) 0.04
90-day mortality, n (%) 2 (3.3%) 0
RFA, radiofrequency ablation; HR, hepatic resection; SD, standard deviation; AFP, alpha-fetoprotein; MELD, Model for End-stage Liver Disease;
LoS, length of stay.
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A comparison of complications classified according to the
Clavien–Dindo system showed the occurrence of six and three
Grade IIIa complications, four and two Grade II complications,
and five and four Grade I complications in the HR and RFA
groups, respectively. Complications in the HR group included
pleural effusion (n = 3), pneumonia (n = 1), myocardial infarction
(n = 1), biloma (n = 2), ileus (n = 2), ascites (n = 1), hyperbiliru-
binaemia >6 (n = 1), renal insufficiency (n = 1) and encephalopa-
thy (n = 2). Complications in the RFA group included severe
oesophagitis (n = 1), encephalopathy (n = 3), cholangitis (n = 1),
ascites (n = 2), renal insufficiency (n = 1) and pneumonia (n = 1).
Recurrence of HCC
Follow-up at a median of 29 months showed tumour recurrences
in 21 (35.0%) RFA-treated patients and 23 (46.0%) HR-treated
patients (P = 0.249). There were no significant differences in the
location of disease recurrence between the treatment groups. In
the HR group, 18 patients had new intrahepatic lesions, two
patients had extrahepatic recurrence, and three patients had both.
In the RFA group, 16 patients had new intrahepatic lesions (two of
which recurred at sites of prior ablation), two patients had extra-
hepatic recurrence, and three patients had both. Treatment of
recurrences included surgical resection, ablation, systemic chemo-
therapy, radiation therapy and chemoembolization (Table 2).
Ablation success as defined in follow-up imaging at 3 months
was achieved in 58 (96.7%) of the patients who received RFA.
During the follow-up, local recurrence at the ablation site was
observed in two of the 58 patients (3.4%). Thus, ablation success
was sustained throughout the follow-up period in 56 of 58
patients (96.6%) and treatment was deemed to have failed in four
of 60 patients (6.7%).
Survival analyses
Overall survival at 1 year, 3 years and 5 years did not differ
between the HR and RFA groups (RFA group: 86%, 50%, 35%,
respectively; HR group: 88%, 68%, 47%, respectively) (Fig. 1).
The median OS was 42 months in RFA-treated patients and
65 months in HR-treated patients (P = 0.222). Similarly, there
were no significant differences between the groups in 1-, 3- and
5-year DFS (RFA group: 68%, 42%, 28%, respectively; HR group:
66%, 42%, 34%, respectively) (Fig. 2). Median DFS was
27 months in the RFA group and 28 months in the HR group (P =
0.823). A subgroup analysis of patients with tumours measuring
2 cm (excluding very early-stage HCC) showed no significant
difference in OS and DFS between the treatment groups (Table 3,
Figs 3 and 4). Likewise, there was no significant difference in OS
and DFS in the subgroups of patients with Child–Pugh class A
cirrhosis (Table 3, Figs 5 and 6). Similarly, no significant differ-
ence in OS and DFS emerged between patients without cirrhosis
and patients with Child–Pugh class B cirrhosis (data not shown).
Discussion
Liver transplantation has been shown to be the ideal treatment for
HCC in terms of longterm outcomes.17 However, its application is
limited by organ shortages and lengthy waiting times. Hepatic
resection is still considered the most effective treatment in
patients with resectable HCC and preserved liver function who are
not candidates for liver transplantation. Assessing which therapy
is optimal is not always easy. In clinical practice, demographics,
tumour size, tumour location, underlying liver disease and
comorbidities influence the surgeon’s decision on whether to
offer RFA or HR to a patient with early HCC. Whether the first-
Table 2 Treatment of recurrences in the hepatic resection (HR) and
radiofrequency ablation (RFA) groups
Treatment HR group
(n = 23), n (%)
RFA group
(n = 21), n (%)
None 7 (30.5%) 5 (23.8%)
TACE alone (range: 1–13
treatments)
8 (34.8%) 4 (19.1%)
Yttrium-90 alone (range: 1–2
treatments)
3 (13.1%) 4 (19.1%)
Resection 1 (4.3%) 2 (9.5%)
Systemic chemotherapy 2 (8.7%) 1 (4.8%)
Radiofrequency ablation 1 (4.3%) 3 (14.2%)
Combination/sequential
treatments (TACE  yttrium-90
 resection  chemotherapy)
1 (4.3%) 2 (9.5%)
TACE, transarterial chemoembolization.
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Figure 1 Kaplan–Meier curves showing overall survival in the hepatic
resection (HR) and radiofrequency ablation (RFA) treatment groups
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line treatment for these patients should comprise HR or RFA
remains a matter of debate in which there are no clear guidelines.
Two randomized trials addressing this issue have been published.
However, one trial concluded that there was no difference in
patient survival between HR and RFA, whereas the other demon-
strated that HR may provide better survival and lower recurrence
than RFA.15,16 Both studies were criticized for their study design,
small sample sizes, differences in baseline characteristics between
groups and high rates of conversion from ablation to surgery.
In the present study, HR and RFA were used as first-line treat-
ments for patients with early-stage HCC who were not candidates
for liver transplantation. Reasons for excluding patients from liver
transplant included active alcohol or illicit drug abuse, age, the
presence of severe comorbidities, psychosocial factors and patient
preferences. Rates of local control efficacy and longterm survival
did not differ statistically between patients undergoing HR and
P = 0.823
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Figure 2 Kaplan–Meier curves showing disease-free survival in the
hepatic resection (HR) and radiofrequency ablation (RFA) treatment
groups
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Figure 3 Kaplan–Meier curves showing overall survival in subgroups
of patients with hepatocellular carcinoma tumours measuring
2 cm in the hepatic resection (HR) and radiofrequency ablation
(RFA) treatment groups
Table 3 Overall and disease-free survival subgroup analysis based on tumour size and degree of cirrhosis
HR group,
tumours of
2 cm
RFA group,
tumours of
2 cm
P-value HR group,
Child–Pugh
class A
RFA group,
Child–Pugh
class A
P-value
Patients, n 36 36 27 40
Overall survival NS NS
1-year 88% 82% 92% 92%
3-year 68% 54% 64% 60%
5-year 52% 42% 52% 42%
Median survival, months 58 42 65 52
Disease-free survival NS NS
1-year 50% 52% 48% 54%
3-year 38% 39% 32% 37%
5-year 28% 24% 24% 18%
Median survival, months 28 24 12 11.5
HR, hepatic resection; RFA, radiofrequency ablation; NS, not significant.
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RFA, respectively, with curative intent. Furthermore, complete
local responses were sustained throughout follow-up (median:
29 months) in 96.5% of patients treated with RFA. Interestingly,
survival rates in the present patients with early-stage HCC were
lower than those reported in previously published studies.18 This
differencemay reflect the fact that patients in theAsian studieswere
younger and were more likely to have hepatitis B than hepatitis C.
In addition, the present study analysed only patients not listed for
transplant and thus possibly selected patients with poorer upfront
prognoses.
A major determinant of survival in patients with HCC refers to
the underlying liver disease.19 As a result, comparisons of the
outcomes of HR and RFA in different studies are potentially
undermined by selection bias because RFA is usually reserved for
patients with worse underlying liver function. This was also noted
in the present study, in which patients in the RFA group were
more often cirrhotic or had Child–Pugh class B cirrhosis. In an
attempt to eliminate this discrepancy, a subgroup analysis of out-
comes in patients with similar background liver disease was per-
formed. This found no statistically significant difference between
outcomes after RFA and HR, respectively, in terms of OS and DFS
in patients with Child–Pugh class A cirrhosis.
Radiofrequency ablation has been recommended for the treat-
ment of patients with smaller tumours because it was previously
considered to be less efficacious for biggerHCCs.20 Over the course
of this study, RFA technology has improved with the development
of newer and larger 5–7-cm probes, which allow the treatment of
P = 0.971
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Figure 4 Kaplan–Meier curves showing disease-free survival in sub-
groups of patients with hepatocellular carcinoma tumours measur-
ing 2 cm in the hepatic resection (HR) and radiofrequency ablation
(RFA) treatment groups
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Figure 5 Kaplan–Meier curves showing overall survival in subgroups
of patients with Child–Pugh class A cirrhosis in the hepatic resection
(HR) and radiofrequency ablation (RFA) treatment groups
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Figure 6 Kaplan–Meier curves showing disease-free survival in sub-
groups of patients with Child–Pugh class A cirrhosis in the hepatic
resection (HR) and radiofrequency ablation (RFA) treatment groups
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larger tumours. It has also been shown to be efficacious in both
tumours measuring <3 cm and HCC tumours of 5 cm.21,22 The
present study included a subgroup analysis to investigate how RFA
compares withHR in patients with tumours of2 cm.This analy-
sis found no difference in OS andDFS subsequent to RFA andHR,
respectively, in patients with larger tumours (2–5 cm), although it
did note a trend towards higher OS after HR. Figure 5 shows
outcomes in patients with Child–Pugh class A cirrhosis and indi-
cates little separation between the groups. The space between the
curves in Fig. 3 may reflect the fact that baseline liver function was
better in theHRgroup and thus patients in this groupwould expect
to achieve better survival. In addition, the analysis may not have
reached statistical significance because the number of patients in
the group was limited.
Radiofrequency ablation is not without limitations and spe-
cific risks should be considered before this technique is
employed. Lesions must be visible by ultrasound and should be
remote from large blood vessels as the heat sink effect may
hinder appropriate tumour control. In addition, care must be
taken to avoid thermal injury to adjacent bile ducts. Further-
more, tumour seeding was observed in 1.8% of patients in a
series by Livraghi et al.12 In the present study, microsatellite
disease next to the primary tumour was detected on final pathol-
ogy, but not on preoperative imaging, in 16.0% of the HR group.
It has been proposed that HR is advantageous because it allows
for the complete resection of tumour tissue along with adjacent
territory that might harbour microsatellite disease and venous
tumour thrombi and thus may lead to a lower frequency of intra-
hepatic recurrence.23 However, the present study found no sig-
nificant difference in intrahepatic recurrences between the HR
and RFA patient groups.
The limitations of this study include its retrospective nature
and the bias inherent in decisions on which treatment should be
given to each patient. In addition, the analysis of OS does not take
into account effects accomplished by subsequent multimodal
treatments. Further, the study sample represented a highly
selected small number of patients. However, although this study
does not define an algorithm for the use of these two modalities,
it does indicate that RFA should be considered as a primary treat-
ment option or as an alternative to surgery in early-stage HCC
because it is minimally invasive, allows for excellent local tumour
control, and incurs a lower rate of complications and a shorter
hospital LoS than HR. Furthermore, Ikeda et al. 24 demonstrated
that RFA is more cost-effective than surgery in the treatment
of small HCCs. Unfortunately, patients affected by HCC will
undergo several treatments during their lives because the recur-
rence rate at 5 years is close to 70%.As a result, minimally invasive
procedures such as RFA are desirable. Patients in whom RFA fails
can be reassessed for HR because survival rates in patients under-
going HR after initial RFA failure and patients undergoing HR as
initial treatment have been found to be identical.25 In conclusion,
the present study finds that RFA is comparable with HR in terms
of OS and DFS. Radiofrequency ablation is a reasonable option as
a first-line treatment for early-stage HCC in well-selected patients
who are not listed for transplantation.
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